Conducting economic evaluation and HTA of advanced health technologies

We are committed to advancing health technology assessment (HTA) methodologies and adapting them to meet the evaluation challenges posed by the most innovative and disruptive health technologies.

WHAT WE DO

Expand all

We conduct studies for a wide range of health technologies including:

  • Pharmaceuticals, including Advanced therapy medicinal products (ATMPs)
  • Medical devices and diagnostics
  • Digital solutions both with and without the use of artificial intelligence
  • Precision medicine technologies
  • Vaccines
  • Healthcare programmes 

We elaborate assessment methods and tools specifically for innovative and disruptive health technologies such as digital therapeutics, AI-based digital solutions, Apps.

RELATED PROJECTS

European_Commission_logo
AI4Lungs

AI-based personalised care for respiratory disease using multi-modal data in patient stratification 
European_Commission_logo
Cinderella

Clinical Validation and multidimensional assessment of an AI-based approach to improve the shared decision-making process and outcomes in Breast Cancer Patients proposed for Locoregional treatment 
icona Research
Lung Cancer App (LuCApp)

LuCApp is a mobile app developed to promote real-time monitoring and management of patients’ symptoms to ultimately improve the quality of life and the delivery of care for patients with lung cancer
European_Commission_logo
Resolve

Creation of a MRD registry and conduction of a multicenter, two-arm, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients with AML or CLL 
bill e melinda found.
The eLMIS & EIR project

Evaluating the impact of electronic Logistic Management Information Systems (eLMIS) and Electronic Immunization Registries (EIR) in low- and middle-income countries 
European_Commission_logo
Sagittarius

A Precision Medicine Trial Leveraging Blood-Based Tumor Genomics To Optimize Treatment In Operable Stage III And High-Risk Stage II Colon Cancer Patients - The Sagittarius Trial